ROBERT ANTON WILSON: What I’m really afraid of is when they decide to legalize it and they come up with a pill, some squib, probably Eli Lilly – as the Bush family own a lot of Eli Lilly – they come up with a pill that contains the derivative of cannabis that kills pain, but it doesn’t get you high and then they’ll charge about 50 dollars a pill, so for real relief from pain it’ll be out of reach for most of the population and they will still go on suffering or buying from black market dealers, meanwhile they’ll have a better excuse to close down the medical marijuana cooperatives – “Hey we got a legal form here and it doesn’t produce that terrible euphoria that’s bad for you” [laughs, smiles] They all complain about euphoria as one of the bad side effects of cannabis, apparently you’re not in your right mind in this country unless you feel vaguely miserable, apprehensive and depressed. If you start feeling euphoric there must be something wrong with you, what the hell! I think euphoria is part of the treatment! There’s a hell of a lot of evidence and a hell of a lot of books starting with Wilhelm Reich on, Prescott, DeMeo, oh there’s ton’s of evidence that feeling good is good for your health. So their attempt to take the joy out of marijuana just means they want you to take longer to heal whatever you use it for if your using it for medical purposes. — RAW.
“Synthetic THC is known as dronabinol. It is available as a prescription drug (under the trade name Marinol) in several countries including the United States and Germany. Watson Pharmaceuticals, Inc. announced on June 29, 2008, the U.S. launch of the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths. Dronabinol is the generic version of Marinol(R)(dronabinol) CIII Capsules. In the United States, Marinol is a Schedule III drug, available by prescription, considered to be non-narcotic and to have a low risk of physical or mental dependence. Efforts to get cannabis rescheduled as analogous to Marinol have not succeeded thus far, though a 2002 petition has been accepted by the DEA. As a result of the rescheduling of Marinol from Schedule II to Schedule III, refills are now permitted for this substance. Marinol has been approved by the FDA in the treatment of anorexia in AIDS patients, as well as for refractory nausea and vomiting of patients undergoing chemotherapy, which has raised much controversy as to why natural THC is still a schedule I drug.
An analog of dronabinol, nabilone, is available commercially in Canada under the trade name Cesamet, manufactured by Valeant. Cesamet has also received FDA approval and has began marketing in the U.S. as of 2006; it is a Schedule II drug.
In April 2005, Canadian authorities approved the marketing of Sativex, a mouth spray for multiple sclerosis patients, who can use it to alleviate neuropathic pain and spasticity. Sativex contains tetrahydrocannabinol together with cannabidiol. It is marketed in Canada by GW Pharmaceuticals, being the first cannabis-based prescription drug in the world. — http://en.wikipedia.org/wiki/Tetrahydrocannabinol